BiomX Q3 net loss $9.2M; cash $8.1M; FDA feedback for BX011 and BX004 positive

BiomX Inc.

Net loss of $9.2M in Q3 2025 vs net income of $9.6M in Q3 2024 due to warrant fair value changes.
Cash and restricted cash $8.1M as of Sep 30, 2025, from $18M at Dec 31, 2024; runway into Q1 2026.
R&D expenses $6.1M, G&A $2.4M; net cash used in operations $22.0M for nine months vs $30.7M in 2024.
FDA provided positive feedback on BX011 clinical pathway for S. aureus diabetic foot infections; Phase 2a planned.
BX004 clinical hold feedback imminent; Phase 2b topline results expected Q1 2026; FDA outlined potential Phase 3 pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.